Investing

Kyverna Therapeutics : KYTX

KYTX

Stock Data

$8.87

$0.07 (0.80%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Kyverna Therapeutics Inc is a pioneering biopharmaceutical company focused on developing innovative cell therapies for autoimmune diseases. Its flagship product, KYV-101, is a cutting-edge treatment designed for lupus nephritis and other severe conditions like systemic sclerosis and multiple sclerosis. Additionally, Kyverna is working on KYV-201, aiming to broaden its impact across multiple autoimmune diseases. With roots tracing back to 2018 and a rebranding from BAIT Therapeutics in 2019, Kyverna is based in Emeryville, California, leading the charge in autoimmune disease treatment.

All Kyverna Therapeutics Articles

1 Article

Trey Thoelcke | Feb 16, 2026 at 9:40 AM EST

Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year

Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up…